Galectin-3 and Blood Group: Binding Properties, Effects on Plasma Levels, and Consequences for Prognostic Performance
暂无分享,去创建一个
R. D. de Boer | M. Kleber | G. Delgado | W. V. van Gilst | J. Schuringa | A. R. van der Velde | Winfried März | H. H. Silljé | Wouter C. Meijers | Saskia de Rond | Elles M. Screever | Carolin Pozder | Janne Suwijn
[1] G. Sinagra,et al. [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.
[2] S. Stowell,et al. Full-Length Galectin-3 Is Required for High Affinity Microbial Interactions and Antimicrobial Activity , 2021, Frontiers in Microbiology.
[3] J. McMurray,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.
[4] C. Forsblom,et al. Relationship between ABO blood groups and cardiovascular disease in type 1 diabetes according to diabetic nephropathy status , 2020, Cardiovascular Diabetology.
[5] M. A. Said,et al. Genetically Determined ABO Blood Group and its Associations With Health and Disease , 2020, Arteriosclerosis, thrombosis, and vascular biology.
[6] Lyanne M. Kieneker,et al. Heart Failure Stimulates Tumor Growth by Circulating Factors , 2018, Circulation.
[7] A. Keren,et al. Clinical Impact of ABO and Rhesus D Blood Type Groups in Patients With Chronic Heart Failure. , 2018, The American journal of cardiology.
[8] R. D. de Boer,et al. Galectin-3 in Heart Failure: An Update of the Last 3 Years. , 2018, Heart failure clinics.
[9] S. Sumner,et al. Blood type biochemistry and human disease , 2016, Wiley interdisciplinary reviews. Systems biology and medicine.
[10] C. Blais,et al. The association between blood group and the risk of vascular disease in Quebec blood donors. , 2016, Blood transfusion = Trasfusione del sangue.
[11] Jian‐Jun Li,et al. ABO blood group system and the coronary artery disease: an updated systematic review and meta-analysis , 2016, Scientific Reports.
[12] G. Lippi,et al. Genetic determinants of extreme longevity: the role of ABO blood group , 2016, Thrombosis and Haemostasis.
[13] R. D. de Boer,et al. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH , 2015, European journal of heart failure.
[14] F. Zannad,et al. Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension , 2015, Hypertension.
[15] J. Dennis,et al. The galectin lattice at a glance , 2015, Journal of Cell Science.
[16] Ruoxiang Jiang,et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. , 2015, JAMA internal medicine.
[17] A. Griffioen,et al. Galectin expression in cancer diagnosis and prognosis: A systematic review. , 2015, Biochimica et biophysica acta.
[18] B. He,et al. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. , 2015, International journal of cardiology.
[19] G. Lippi,et al. The intriguing relationship between the ABO blood group, cardiovascular disease, and cancer , 2015, BMC Medicine.
[20] R. Malekzadeh,et al. Mortality and cancer in relation to ABO blood group phenotypes in the Golestan Cohort Study , 2015, BMC Medicine.
[21] W. März,et al. Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies. , 2015, Journal of the American Society of Nephrology : JASN.
[22] K. Thangaraj,et al. Reduced prevalence of placental malaria in primiparae with blood group O , 2014, Malaria Journal.
[23] R. D. de Boer,et al. Renal Handling of Galectin‐3 in the General Population, Chronic Heart Failure, and Hemodialysis , 2014, Journal of the American Heart Association.
[24] Sanjiv J. Shah,et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. , 2014, American heart journal.
[25] R. D. de Boer,et al. The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure , 2014, Expert review of molecular diagnostics.
[26] N. Mandal,et al. Distribution of ABO Blood Group and Major Cardiovascular Risk Factors with Coronary Heart Disease , 2013, BioMed research international.
[27] Massimo Franchini,et al. ABO blood group: old dogma, new perspectives , 2013, Clinical chemistry and laboratory medicine.
[28] M. Reilly,et al. ABO Blood Groups and Cardiovascular Diseases , 2012, International journal of vascular medicine.
[29] R. D. de Boer,et al. Plasma renin and outcome in the community: data from PREVEND. , 2012, European heart journal.
[30] J. Manson,et al. ABO Blood Group and Risk of Coronary Heart Disease in Two Prospective Cohort Studies , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[31] G. Lippi,et al. ABO blood group, hypercoagulability, and cardiovascular and cancer risk , 2012, Critical reviews in clinical laboratory sciences.
[32] P. Harst,et al. The fibrosis marker galectin‐3 and outcome in the general population , 2012, Journal of internal medicine.
[33] P. D. de Groot,et al. Identification of Galectin-1 and Galectin-3 as Novel Partners for Von Willebrand Factor , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[34] Claudio Michelassi,et al. ABO blood group alleles: A risk factor for coronary artery disease. An angiographic study. , 2010, Atherosclerosis.
[35] W. März,et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. , 2010, European heart journal.
[36] A. Wu,et al. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. , 2010, Clinical biochemistry.
[37] David F. Smith,et al. Innate immune lectins kill bacteria expressing blood group antigen , 2010, Nature Medicine.
[38] A. Paterson,et al. Genome-Wide Association Identifies the ABO Blood Group as a Major Locus Associated With Serum Levels of Soluble E-Selectin , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[39] D. J. Veldhuisen,et al. Galectin‐3: a novel mediator of heart failure development and progression , 2009, European journal of heart failure.
[40] S. Chanock,et al. ABO blood group and the risk of pancreatic cancer. , 2009, Journal of the National Cancer Institute.
[41] D. Sane,et al. ABO blood types: influence on infarct size, procedural characteristics and prognosis. , 2008, Thrombosis research.
[42] David F. Smith,et al. Galectin-1, -2, and -3 Exhibit Differential Recognition of Sialylated Glycans and Blood Group Antigens* , 2008, Journal of Biological Chemistry.
[43] B. Jilma,et al. Von Willebrand Factor in Cardiovascular Disease: Focus on Acute Coronary Syndromes , 2008, Circulation.
[44] M. Daniel,et al. Is there an association between blood group O and epistaxis? , 2006, The Journal of Laryngology & Otology.
[45] G. Lippi,et al. Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications , 2007, Thrombosis journal.
[46] D. Pascual-Figal,et al. [Clinical determinants and prognostic value of hemoglobin in hospitalized patients with systolic heart failure]. , 2007, Revista espanola de cardiologia.
[47] U. Vischer,et al. von Willebrand factor, endothelial dysfunction, and cardiovascular disease , 2006, Journal of thrombosis and haemostasis : JTH.
[48] M. Drazner,et al. Impact of Body Mass and Body Composition on Circulating Levels of Natriuretic Peptides: Results From the Dallas Heart Study , 2005, Circulation.
[49] Ralph D'Agostino,et al. Relative Importance of Borderline and Elevated Levels of Coronary Heart Disease Risk Factors , 2005, Annals of Internal Medicine.
[50] D. Staub,et al. B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison. , 2005, Kidney international.
[51] Toshihiko Oka,et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. , 2002, Biochimica et biophysica acta.
[52] W. März,et al. Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. , 2001, Pharmacogenomics.
[53] J A Kors,et al. Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study , 2000 .
[54] H. Crijns,et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND I , 2000, The American journal of cardiology.
[55] L. Almasy,et al. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[56] R. Nagel,et al. Role of A and B blood group antigens in the expression of adhesive activity of von Willebrand factor , 2000, British journal of haematology.
[57] K. Jeng,et al. The adhesive specificity of the soluble human lectin, IgE-binding protein, toward lipid-linked oligosaccharides. Presence of the blood group A, B, B-like, and H monosaccharides confers a binding activity to tetrasaccharide (lacto-N-tetraose and lacto-N-neotetraose) backbones. , 1994, Biochemistry.
[58] J. Lowe. 7 The blood group-specific human glycosyltransferases , 1993 .
[59] K. Titani,et al. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. , 1992, The Journal of biological chemistry.
[60] Henrik Clausen,et al. Molecular genetic basis of the histo-blood group ABO system , 1990, Nature.
[61] K. Shadan,et al. Available online: , 2012 .